Odyssey Health, Inc. presents a Company update and recap of its concussion drug development program. Concussions represent an ‘unmet' medical need and affect tens of millions worldwide. Odyssey acquired the intellectual property and all rights to the concussion drug in March 2021.

Since the acquisition, Odyssey has added key industry experts to its management, made significant progress in the drug development program, and completed a Phase I human clinical trial. Key successes include: Adding two key executives to the management team that have pertinent pharmaceutical experience bringing drugs through the clinical process and to the market. Completion of FDA-required IND enabling studies for a Phase I human trial.

This work was performed in partnership with multiple GMP/GLP third party vendors. Development of a nanoparticle spray-dried formulation for intranasal delivery to enhance brain uptake. This work was performed in partnership with UK partner under GMP regulations.

Development and GMP manufacture of novel breath-propelled intranasal delivery device with California based engineering partner. Patent application filed for novel breath-propelled intranasal delivery device. Contracted with world-class contract research organizations, Avance Clinical Pty Ltd. and Nucleus Networks to conduct the Phase I clinical trial.

Completion of the Phase I human clinical trial, proving the drug is safe and well tolerated. Phase I human clinical trial showed no drug accumulation through the 10-day patient follow-up visit.